Literature DB >> 770046

Influence of magnesium and aluminum hydroxide mixture on chlordiazepoxide absorption.

D J Greenblatt, R I Shader, J S Harmatz, K Franke, J Koch-Weser.   

Abstract

Ten healthy male subjects ingested 25 mg of chlordiazepoxide hydrochloride (Librium) with 100 ml of water or with 100 ml of magnesium and aluminum hydroxide (Maalox) in a single-dose crossover study. Multiple venous blood samples drawn during the first 24 hr after each dose were assayed for concentrations of chlordiazepoxide and its major metabolite, desmethylchlordiazepoxide. The antacid prolonged the mean chlordiazepoxide absorption half-time from 11 to 24 min, and in 6 of 10 subjects delayed achievement of the peak blood concentration by from 0.5 to 3.0 hrs. The formation of desmethylclordiazepoxide was also slowed. The areas under the 24 hr blood concentration curve for chlordiazepoxide and for its metabolite were not influenced by the antacid. The apparent elimination half-life of chlordiazepoxide (8.4 and 8.2 hr) was not significantly affected. Administration of chlordiazepoxide with antacid reduces the rate of its absorption but does not alter the completeness of absorption or the apparent rate of elimination.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 770046     DOI: 10.1002/cpt1976192234

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  14 in total

1.  Pharmacokinetics of intravenous and oral chlordesmethyldiazepam in patients on regular haemodialysis.

Authors:  J Sennesael; D Verbeelen; L Vanhaelst; R Pirola; S R Bareggi
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

Review 2.  Antacid therapy and drug kinetics.

Authors:  A Hurwitz
Journal:  Clin Pharmacokinet       Date:  1977 Jul-Aug       Impact factor: 6.447

3.  Pharmacokinetic and biopharmaceutic profile of chlordiazepoxide HC1 in healthy subjects: single-dose studies by the intravenous, intramuscular, and oral routes.

Authors:  H G Boxenbaum; K A Geitner; M L Jack; W R Dixon; H E Spiegel; J Symington; R Christian; J D Moore; L Weissman; S A Kaplan
Journal:  J Pharmacokinet Biopharm       Date:  1977-02

Review 4.  Interactions affecting drug absorption.

Authors:  P G Welling
Journal:  Clin Pharmacokinet       Date:  1984 Sep-Oct       Impact factor: 6.447

5.  Interaction between phenytoin and antacids.

Authors:  V K Kulshrestha; M Thomas; J Wadsworth; A Richens
Journal:  Br J Clin Pharmacol       Date:  1978-08       Impact factor: 4.335

6.  Failure of antacids to alter the pharmacokinetics of phenytoin.

Authors:  L S O'Brien; M L Orme; A M Breckenridge
Journal:  Br J Clin Pharmacol       Date:  1978-08       Impact factor: 4.335

7.  Adverse effects of anti-ulcer drugs.

Authors:  D A Henry; M J Langman
Journal:  Drugs       Date:  1981-06       Impact factor: 9.546

Review 8.  Pharmacokinetic interactions with antiepileptic drugs.

Authors:  E Perucca
Journal:  Clin Pharmacokinet       Date:  1982 Jan-Feb       Impact factor: 6.447

9.  Effects of end stage renal disease and aluminium hydroxide on triazolam pharmacokinetics.

Authors:  P D Kroboth; R B Smith; M R Silver; R Rault; M I Sorkin; J B Puschett; R P Juhl
Journal:  Br J Clin Pharmacol       Date:  1985-06       Impact factor: 4.335

Review 10.  Clinical pharmacokinetics of chlordiazepoxide.

Authors:  D J Greenblatt; R I Shader; S M MacLeod; E M Sellers
Journal:  Clin Pharmacokinet       Date:  1978 Sep-Oct       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.